Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant (antimetabolite) presented as a delayed‑release tablet for oral use. It helps prevent organ rejection in patients who have received kidney, heart or other solid organ transplants.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is used to prevent rejection in solid‑organ transplantation by suppressing lymphocyte activity.

- Renal transplantation: reduces the risk of acute and chronic graft rejection and supports long‑term graft survival. - Cardiac transplantation: lowers incidence of rejection episodes and helps maintain cardiac graft function. - Other solid organ transplants: maintains immunologic tolerance and decreases the likelihood of graft loss in liver, lung and pancreas transplants.

Myfortic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: occasional upset stomach or feeling of queasiness. - Diarrhea: loose stools that may be mild to moderate. - Headache: transient cranial discomfort. - Tremor: fine shaking of hands or limbs.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells, increasing infection risk. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Malignancy: rare reports of post‑transplant lymphoproliferative disorder or other cancers.

Before initiating Myfortic, clinicians should consider several safety measures.

- Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia. - Assess renal function: check serum creatinine and glomerular filtration rate periodically. - Avoid live vaccines: live attenuated vaccines can cause infection in immunosuppressed patients. - Use contraception: pregnancy category D; effective contraception is required for women of childbearing potential. - Store below 25°C: keep in the original packaging, protect from moisture and excessive heat.

Myfortic can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: increases mycophenolic acid exposure, raising toxicity risk. - Rifampin: induces metabolism and reduces drug levels, compromising efficacy. - Antacids containing aluminum or magnesium: decrease absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression; monitor blood counts. - Valganciclovir: may enhance cytopenia; adjust dosing as needed.